WaveData’s compilation of the fastest-rising UK generics prices in December showed several products across multiple presentations more than doubling their average trade prices to independent pharmacists.

Teva CEO Kåre Schultz has weighed in on Novartis’ plans to conduct a strategic review for its Sandoz unit, while also airing frustrations over continued delays for complex products in the US.

This year’s annual IQVIA report into European biosimilar competition has found savings in the market are at record highs, but Medicines for Europe says more action is needed to translate the potential of biosimilars into real-world changes.

Topiramate tablets took four places in our table of average UK generic price rises for November 2021, as prices as much as trebled for the epilepsy treatment. However, one product ranked even higher with a 231% average price rise.

Uptake is expected to be “rapid” once Humira biosimilars launch in the US, according to Sean McGowan, senior director of biosimilars at AmerisourceBergen. Meanwhile, milestone first approvals for interchangeable and ophthalmic biosimilars show that the US biosimilars market is moving in the right direction, he tells Generics Bulletin in an exclusive Q&A.

Two generics saw their average UK trade prices almost double in October for very different reasons, according to the latest pricing information from market researcher WaveData.

The Biosimilars Forum, in partnership with the Pacific Research Institute, has released a report that shows state-by-state cost savings for the US if biosimilars were able to capture a market share of 75%. Meanwhile, the Association for Accessible Medicines has also released its complete 2021 US Generic And Biosimilar Medicines Savings Report, discouraging reducing incentives for patent challenges and early generic entry.

Amgen’s recent study on biosimilars trends has outlined the importance of US policy in the success of the biosimilars marketplace, insisting on the importance of increased competition and effective reimbursement and education policies. But with interests in innovative biologics as well as biosimilars, the company has also emphasized that pro-biosimilars policies must not stifle innovation and compromise free competition.

Benign prostatic hyperplasia treatment indoramin topped the UK’s steepest generic price rises in September with an average price that more than trebled, according to the latest figures from WaveData.